Welcome to our dedicated page for Amarin news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin stock.
Amarin Corporation plc develops and commercializes cardiovascular therapeutics centered on icosapent ethyl, marketed as VASCEPA in the United States and VAZKEPA in Europe. Company news commonly covers product revenue, cash flow, U.S. prescription trends, partner-led international commercialization, and European distribution under an exclusive licensing and supply agreement with Recordati.
Updates also include medical-society guideline discussions, REDUCE-IT analyses, peer-reviewed publications, and scientific meeting presentations on cardiovascular risk reduction, elevated triglycerides, eicosapentaenoic acid, and lipoprotein(a) oxidation.
Amarin (NASDAQ: AMRN) reported Q4 and full‑year 2025 results showing operational improvements and a tighter cost base. Total net revenue was $49.2M in Q4 (down 21% YoY); operating loss narrowed to $6.3M; cash and investments were $302.6M with no debt.
The company realized $31M of targeted $70M cost savings and recorded $36.2M of restructuring charges in 2025, with remaining charges expected in early 2026. The company finalized a long‑term European license and supply agreement for VAZKEPA and retained U.S. VASCEPA market leadership.
Amarin (NASDAQ: AMRN) used American Heart Month (Feb 23, 2026) to urge urgent action on underutilized, guideline‑supported cardiovascular therapies.
The company highlighted that 48.9% of U.S. adults live with CVD and cited evidence that cumulative CV event incidence can reach ~40% over 10 years, calling to “Review, Reassess, Refocus” care to close treatment gaps.
Amarin (NASDAQ: AMRN) will report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026. A pre-market press release will be issued, followed by a conference call with senior management at 8:00 a.m. ET.
Investors can join via telephone (US: 888-506-0062; international: 973-528-0011, access code 675507) or via webcast on the company Investor Relations website. A replay will be available online and by phone through August 25, 2026.
Amarin (NASDAQ: AMRN) commented on recent therapeutic advances for patients with elevated triglycerides and said its VASCEPA/VAZKEPA (icosapent ethyl) franchise is well positioned to benefit from broader category commercialization. The company noted VASCEPA has been prescribed >25 million times, is FDA approved for severe hypertriglyceridemia (TG ≥500 mg/dL) and for cardiovascular risk reduction as an adjunct to statin therapy, and cited REDUCE-IT results showing a 25% relative reduction in cardiovascular events in 8,179 patients. Amarin also highlighted a 2025 exclusive license with Recordati for commercialization across 59 countries, with VAZKEPA available in >20 countries.
Amarin (NASDAQ:AMRN) reported preliminary unaudited 2025 results and operational milestones, highlighting a year-end cash balance of $303 million, positive cash flow in Q4 2025 achieved ahead of prior expectations, and a debt-free balance sheet. The company realized ~50% of an estimated $70 million OPEX savings from its 2025 restructuring and expects the full savings by June 30, 2026. FY 2025 net revenue is expected to be $212–$217 million, with Q4 revenue of $48–$53 million. Amarin completed a long-term exclusive license and supply agreement with Recordati for VAZKEPA in 59 countries and secured regulatory approvals in South Korea and Singapore.
Amarin (NASDAQ: AMRN) presented a new REDUCE-IT post hoc aspirin analysis at AHA Scientific Sessions 2025 showing that icosapent ethyl significantly reduced cardiovascular events in high-risk, statin-treated patients with elevated triglycerides.
Among 8,179 participants (6,179 on aspirin), icosapent ethyl cut the primary endpoint by 28% in aspirin users (P<0.0001), with an absolute risk reduction 5.9% and NNT 17. Total primary events were reduced by 36% (RR 0.64; 95% CI 0.56–0.74). In the secondary prevention aspirin subgroup (n=4,867) total events fell 39% (RR 0.61; 95% CI 0.53–0.70).
The analysis found consistent benefit with or without aspirin and reported a safety profile in aspirin users consistent with the overall trial population.
Amarin (NASDAQ: AMRN) will present new analyses and mechanistic studies at the American Heart Association Scientific Sessions 2025 in New Orleans, Nov 7–10, 2025.
Highlighted items include REDUCE-IT analyses of icosapent ethyl (VASCEPA/VAZKEPA) assessing cardiovascular outcomes with or without baseline aspirin use, plus mechanistic data on EPA effects on lipoprotein(a) oxidation, anti-inflammatory actions, and endothelial protection. Specific presentations are scheduled Nov 9–10, 2025, across Abstract Board, Population Science, and Basic Science zones.
Amarin (NASDAQ: AMRN) reported Q3 2025 results showing a shift toward a fully partnered international commercial model and initial margin improvement after a June 2025 global restructuring.
Key Q3 2025 metrics: Total net revenue $49.7M (+17% YoY), Product revenue $48.6M (+16% YoY) driven by U.S. product revenue $40.9M (+34% YoY). Operating loss narrowed to $11.1M (operating margin -22%) from $25.2M year-ago. Net loss was $7.7M ($0.02/share). SG&A fell 47%; restructuring charges of $9.4M were recorded. Cash and investments totaled $286.6M and the company is debt free, targeting sustainable positive free cash flow in 2026.
Amarin (NASDAQ:AMRN) praised the FDA for updating fenofibrate labeling on Oct 27, 2025, to state a lack of cardiovascular benefit and to add safety language and a narrowed indication.
The label cites two large diabetes trials and PROMINENT, and warns of increased rhabdomyolysis risk when fibrates are combined with statins. The release notes >11 million US fibrate prescriptions in 2023, >60% co-prescribed with statins, and ~2 million fibrate patients in Western Europe.
Amarin said the change should shift prescribing toward FDA-approved, outcome-proven therapies such as VASCEPA (icosapent ethyl).
Amarin (NASDAQ: AMRN) will report third quarter 2025 financial results and host a conference call on Wednesday, October 29, 2025.
The company will release results in pre-market hours followed by a live call with senior management at 8:00 a.m. ET. Investors can join via telephone (US: 877-545-0523; International: 973-528-0016; Access Code: 459510) or via webcast on the Investor Relations website at www.amarincorp.com. A replay will be available by phone (US: 877-481-4010; International: 919-882-2331; Access Code: 53008) and online through the Investor Relations site beginning shortly after the call and available until March 29, 2026.